The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder
cancer) is poor, while the incidence of these cancers is increasing. Most patients are …

FGFR2 rearrangements resulting in dysregulated signaling are drivers of
cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic …

Abstract Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …

Background and Aim Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are
increasingly well characterized, but their impact on outcome and prognosis remains …

Background: Molecular profiling is becoming increasingly relevant in the management of
patients with advanced cancer; to identify targetable aberrations and prognostic markers to …

Background Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a
dismal prognosis. Recently, several actionable genetic aberrations were identified with …

Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately
15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral …

Biliary tract cancers constitute approximately 3% of gastrointestinal malignancies with poor
prognosis. Surgical therapy is the main form of treatment in localised disease; however, for …

Cancer of unknown primary (CUP) is a syndrome defined by clinical absence of a primary
cancer after standardised investigations. Gene expression profiling (GEP) and DNA …

Conclusions In a multicenter study of treatment‐naïve PBC patients, we identified two cutoffs
(LSM≤ 6.5 and> 11.0 kPa) able to discriminate at diagnosis the absence or presence …